Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000542-200406000-00042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Patients with Myocardial Injury After Noncardiac Surgery: A Retrospective Chart Review.
CJC Open
January 2025
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Background: Myocardial injury after noncardiac surgery (MINS) is associated with an increased incidence of cardiac morbidity and mortality. Little is known about how these patients are managed.
Methods: We performed a single-centre retrospective chart review of patients referred to a postoperative clinic with the diagnosis of MINS.
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.
Cardiovasc Diabetol
January 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and function and/or abnormal cardiac biomarker concentrations.
Objective: To compare the evolution of four DbMD groups based on biomarkers alone, systolic and diastolic dysfunction alone, or their combination.
Cangrelor in Patients Undergoing Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest.
J Clin Med
December 2024
Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
: Cangrelor provides rapid platelet inhibition, making it a potential option for out-of-hospital cardiac arrest (OHCA) survivors undergoing percutaneous coronary intervention (PCI). However, clinical data on its use after OHCA are limited. This study investigates in-hospital outcomes of cangrelor use in this population.
View Article and Find Full Text PDFBiomarker profiles that differentiate type-1 and type 2 myocardial infarction.
Heart Lung
January 2025
University of Foggia, Department of Medical and Surgical Sciences, Foggia, Italy. Electronic address:
Background: It is crucial to distinguish type-1 myocardial infarction (T1MI) from type-2 myocardial infarction (T2MI) at admission and during hospitalization to avoid unnecessary invasive exams and inappropriate admissions to the acute cardiac care unit.
Objectives: The purpose of the study was to define a simple profile derived from commonly used biomarkers to differentiate T1MI from T2MI.
Methods: We prospectively enrolled in an observational study 213 iconsecutive patients with a provisional diagnosis of non-ST-elevation acute myocardial infarction (NSTEMI) admitted to the Cardiology Department.
Research on the mechanism of the anti-myocardial infarction effect of the Qiliqiangxin capsule on heart failure rats via nontargeted metabolomics and lipidomics.
BMC Cardiovasc Disord
December 2024
Jiangxi University of Chinese Medicine, Jiangxi, China.
Article Synopsis
- The Qi Li Qiang Xin (QLQX) capsule shows promise in treating chronic heart failure, with the study aiming to uncover its mechanisms through metabolomics and lipidomics analysis.
- A rat model of heart failure was used to assess the effects of QLQX compared to a control group (SHAM), a myocardial infarction (MI) group, and a valsartan group, with various metrics for cardiac function and morphology being measured.
- Results indicated that QLQX improved heart function and reduced heart failure markers, while metabolomics analysis identified 17 significant plasma metabolites that were beneficially affected by QLQX treatment, indicating its role in biochemical pathways associated with heart health.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!